Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood

This study has been completed.
Sponsor:
Information provided by:
Abbott
ClinicalTrials.gov Identifier:
NCT00300482
First received: March 7, 2006
Last updated: June 3, 2009
Last verified: June 2009
  Purpose

The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + rosuvastatin calcium combination therapy with ABT-335 and rosuvastatin calcium monotherapy in subjects with multiple abnormal lipid levels in the blood.


Condition Intervention Phase
Dyslipidemia
Coronary Heart Disease
Mixed Dyslipidemia
Drug: ABT-335
Drug: Rosuvastatin Calcium
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Rosuvastatin Calcium Combination Therapy to Fenofibric Acid and Rosuvastatin Calcium Monotherapy in Subjects With Mixed Dyslipidemia

Resource links provided by NLM:


Further study details as provided by Abbott:

Primary Outcome Measures:
  • Mean Percent Change in Triglycerides From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]
  • Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]
  • Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean Percent Change in Non-Low-Density Lipoprotein Cholesterol (Non-HDL-C)From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]
  • Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]
  • Mean Percent Change in Total Cholesterol From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]
  • Mean Percent Change in Lipoprotein Apo B (Apo B) From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]
  • Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit [ Time Frame: Baseline to 12 Weeks ] [ Designated as safety issue: No ]

Enrollment: 1445
Study Start Date: March 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
ABT-335 + 10 mg rosuvastatin
Drug: ABT-335
135 mg, daily, 12 weeks
Other Name: ABT-335
Drug: Rosuvastatin Calcium
Daily, 12 weeks, see Arm Description for dosage information
Other Name: Rosuvastatin
Active Comparator: B
ABT-335 + 20 mg rosuvastatin
Drug: ABT-335
135 mg, daily, 12 weeks
Other Name: ABT-335
Drug: Rosuvastatin Calcium
Daily, 12 weeks, see Arm Description for dosage information
Other Name: Rosuvastatin
Placebo Comparator: C
ABT-335 monotherapy
Drug: ABT-335
135 mg, daily, 12 weeks
Other Name: ABT-335
Drug: Placebo
Daily, 12 weeks, see Arm Description for information regarding placebo type
Other Name: Placebo
Placebo Comparator: D
10 mg rosuvastatin monotherapy
Drug: Rosuvastatin Calcium
Daily, 12 weeks, see Arm Description for dosage information
Other Name: Rosuvastatin
Drug: Placebo
Daily, 12 weeks, see Arm Description for information regarding placebo type
Other Name: Placebo
Placebo Comparator: E
20 mg rosuvastatin monotherapy
Drug: Rosuvastatin Calcium
Daily, 12 weeks, see Arm Description for dosage information
Other Name: Rosuvastatin
Drug: Placebo
Daily, 12 weeks, see Arm Description for information regarding placebo type
Other Name: Placebo
Placebo Comparator: F
40 mg rosuvastatin monotherapy
Drug: Rosuvastatin Calcium
Daily, 12 weeks, see Arm Description for dosage information
Other Name: Rosuvastatin
Drug: Placebo
Daily, 12 weeks, see Arm Description for information regarding placebo type
Other Name: Placebo

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with mixed dyslipidemia

Exclusion Criteria:

  • Subjects with unstable medical conditions or medical conditions considered inappropriate in a clinical trial.
  • Patients who are taking certain medications or unstable dose of specific medications.
  • Women who are pregnant or plan on becoming pregnant or women who are lactating.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00300482

Locations
United States, Illinois
Global Medical Information
North Chicago, Illinois, United States, 60064
Sponsors and Collaborators
Abbott
Investigators
Principal Investigator: Maureen Kelly, MD Abbott
  More Information

Additional Information:
No publications provided by Abbott

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Maureen Kelly, MD, Abbott
ClinicalTrials.gov Identifier: NCT00300482     History of Changes
Other Study ID Numbers: M05-748
Study First Received: March 7, 2006
Results First Received: January 14, 2009
Last Updated: June 3, 2009
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Abbott:
Dyslipidemia
Coronary Heart Disease
Mixed Dyslipidemia

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Dyslipidemias
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Calcium, Dietary
Fenofibric acid
Rosuvastatin
Bone Density Conservation Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on August 19, 2014